BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 12360278)

  • 1. Ligand-targeted therapeutics in anticancer therapy.
    Allen TM
    Nat Rev Cancer; 2002 Oct; 2(10):750-63. PubMed ID: 12360278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted toxins.
    Frankel AE; Kreitman RJ; Sausville EA
    Clin Cancer Res; 2000 Feb; 6(2):326-34. PubMed ID: 10690507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody targeted drugs as cancer therapeutics.
    Schrama D; Reisfeld RA; Becker JC
    Nat Rev Drug Discov; 2006 Feb; 5(2):147-59. PubMed ID: 16424916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel therapies for malignant gliomas: a local affair?
    Rainov NG; Söling A; Heidecke V
    Neurosurg Focus; 2006 Apr; 20(4):E9. PubMed ID: 16709040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymer conjugates as anticancer nanomedicines.
    Duncan R
    Nat Rev Cancer; 2006 Sep; 6(9):688-701. PubMed ID: 16900224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ligand-based targeted therapy for cancer tissue.
    Das M; Mohanty C; Sahoo SK
    Expert Opin Drug Deliv; 2009 Mar; 6(3):285-304. PubMed ID: 19327045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cannabinoid receptor ligands as potential anticancer agents--high hopes for new therapies?
    Oesch S; Gertsch J
    J Pharm Pharmacol; 2009 Jul; 61(7):839-53. PubMed ID: 19589225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
    Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
    Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted cancer therapeutics.
    Hait WN; Hambley TW
    Cancer Res; 2009 Feb; 69(4):1263-7; discussion 1267. PubMed ID: 19208830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-cytotoxic agent conjugates for cancer therapy.
    Chen J; Jaracz S; Zhao X; Chen S; Ojima I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):873-90. PubMed ID: 16296784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy.
    Brumlik MJ; Daniel BJ; Waehler R; Curiel DT; Giles FJ; Curiel TJ
    Expert Opin Drug Deliv; 2008 Jan; 5(1):87-103. PubMed ID: 18095930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of histone deacetylase inhibitors for cancer treatment.
    Marchion D; Münster P
    Expert Rev Anticancer Ther; 2007 Apr; 7(4):583-98. PubMed ID: 17428177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases.
    Low PS; Henne WA; Doorneweerd DD
    Acc Chem Res; 2008 Jan; 41(1):120-9. PubMed ID: 17655275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-conjugated monoclonal antibodies for the treatment of cancer.
    Lambert JM
    Curr Opin Pharmacol; 2005 Oct; 5(5):543-9. PubMed ID: 16087399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
    Faivre S; Djelloul S; Raymond E
    Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular-targeted therapies: lessons from years of clinical development.
    Rosa DD; Ismael G; Lago LD; Awada A
    Cancer Treat Rev; 2008 Feb; 34(1):61-80. PubMed ID: 17826917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
    Mazor Y; Noy R; Wels WS; Benhar I
    Cancer Lett; 2007 Nov; 257(1):124-35. PubMed ID: 17698286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CLL immunotoxins.
    Frankel AE; Kreitman RJ
    Leuk Res; 2005 Sep; 29(9):985-6. PubMed ID: 16038723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoclonal antibody therapeutics and apoptosis.
    Ludwig DL; Pereira DS; Zhu Z; Hicklin DJ; Bohlen P
    Oncogene; 2003 Dec; 22(56):9097-106. PubMed ID: 14663488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.